| Company Name | Bayer Taiwan Co., Ltd. |
|---|---|
| Protocol Number | XA1402 (Impact 17237) |
| Title of Study | Xarelto® for Long-term and Initial Anticoagulation in Venous Thromboembolism (VTE) in Latin America, EMEA and Asia |
| Primary Objective | Following the findings of the clinical trials in drug development, this globalnon-interventional cohort field study will investigate rivaroxaban under clinical practice conditions in comparison with current standard of care for patients with acute deep vein thrombosis (DVT) and/or pulmonary embolism (PE). |
| Number of Sites | Expected to have 8 |
| Period of Study | From：2014-11-1 to：2016-10-31 |
| Number of Patients | 200人 |
| IRB Approval Date | Currently under review |
| Publication Plan / Date | TBD |
